Loading stock data…
$12.95-0.05 (-0.38%)
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia.
| Metric (USD) | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — |
| Operating Income | -$4.45M↓ | -$3.79M↓ | -$1.58M↓ | -$1.22M |
| Net Income | -$4.50M↓ | -$3.75M↓ | -$1.89M↓ | -$1.71M |
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel,...